Further sub-group analysis of multiple clinic-pathological features of TCGA-LIHC samples based on disease stages, gender, age, and tumor grade showed that the expression of TSP50 was significantly higher in HCC patients than normal controls (Fig. 1B–E). The gene discussed is PRSS50; the disease is hepatocellular carcinoma.